ACR Image Metrix, a global imaging contract research organisation (CRO) based in the American College of Radiology Clinical Research Center in Philadelphia, US, has welcomed Kathy Freeman as business development manager for the East Coast of the US.
Freeman has extensive experience in sales strategies, team leadership and new market development.
Prior to joining ACR Image Metrix, Freeman held key positions within niche CRO organisations, where she landed numerous contracts in the pharmaceutical and biotech market. She began her career selling specialist pharmaceuticals.
ACR Image Metrix provides imaging CRO services to assist pharmaceutical, biotech and medical device companies around the world.
ACR Image Metrix hires Kathy Freeman
As business development manager for the US East Coast
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development
PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific
The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape